🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Global Health Concern

Gonorrhoea infections are increasing globally, with figures suggesting over 82 million instances per year. Especially elevated rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the face of increasing worldwide cases, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This approval represents a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to results released by a prominent scientific publication, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which involves a dual-drug approach. The trial enrolled nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in many regions with limited resources.

Doctors directly involved have voiced hope. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is viewed as crucial to lessen the impact of the disease for people and to prevent the spread of untreatable gonorrhoea globally.